Rheumatoid arthritis (RA) is treated with a group of medications designed to reduce joint inflammation, slow disease progression, and prevent long-term damage. These include disease-modifying antirheumatic drugs (DMARDs), biologic agents, targeted synthetic DMARDs, nonsteroidal anti-inflammatory drugs (NSAIDs), and corticosteroids. Early initiation of DMARDs improves outcomes.
RA is an autoimmune disorder where the immune system attacks joint linings, causing pain, swelling, and eventual joint destruction. Without treatment, 70% of patients develop structural joint damage within five years, according to the American College of Rheumatology (ACR). The goal of therapy is to achieve low disease activity or remission, which reduces disability and improves quality of life.
Medications for RA target different parts of the immune response. Conventional DMARDs like methotrexate suppress broad immune activity. Biologic DMARDs block specific proteins such as TNF-alpha or IL-6 that drive inflammation. Targeted synthetic DMARDs inhibit intracellular signaling pathways involved in immune cell activation.
Methotrexate, taken once weekly, is the most effective first-line DMARD. It reduces inflammatory markers like CRP and ESR by 50% in 60% of patients within six months. Its mechanism involves inhibiting dihydrofolate reductase, disrupting DNA synthesis in rapidly dividing immune cells. Patients typically start at 7.5 mg orally, increasing to 20-25 mg weekly based on tolerance and lab monitoring.
Corticosteroids like prednisone provide rapid symptom relief but are not used long-term due to side effects. A daily dose of 5-10 mg reduces flare symptoms within days. They are often used short-term while waiting for slower-acting DMARDs to take effect. Long-term use increases risk of osteoporosis, cataracts, and diabetes.
The following table outlines major drug classes used in RA treatment, their typical dosing, and key indications.
| Drug Class | Examples | Dosing Frequency | Primary Use |
|---|---|---|---|
| Conventional DMARDs | Methotrexate, leflunomide | Once weekly (methotrexate) | First-line therapy; slow disease progression |
| Biologic DMARDs | Adalimumab, etanercept, infliximab | Subcutaneous injection every 2 weeks | For moderate-to-severe RA unresponsive to conventional DMARDs |
| Targeted Synthetic DMARDs | JAK inhibitors (tofacitinib, baricitinib) | Oral, twice daily | Alternative for patients who cannot tolerate biologics |
| NSAIDs | Ibuprofen, naproxen | Twice daily, as needed | Symptom relief only; do not alter disease course |
| Corticosteroids | Prednisone | Once daily, tapering over weeks | Short-term flare control |
Biologic DMARDs are administered via subcutaneous injection or IV infusion. Adalimumab, a TNF inhibitor, is given at 40 mg every two weeks. It reduces swollen joint counts by half in 70% of patients after 12 weeks. However, it increases infection risk-serious infections occur in 1.5% of users annually, per FDA safety reports.
Tofacitinib, a JAK inhibitor, blocks Janus kinase enzymes involved in cytokine signaling. It's taken orally at 10 mg twice daily. Clinical trials show it reduces signs of inflammation in 60% of patients within 12 weeks. But it carries a black-box warning for increased risk of blood clots, cancer, and death in patients over 50 with cardiovascular risk factors.
Many patients assume NSAIDs like ibuprofen can stop joint damage. This is incorrect. NSAIDs relieve pain and swelling but do not modify disease progression. A 2021 study in Arthritis & Rheumatology found that patients using only NSAIDs had higher rates of radiographic joint erosion compared to those on methotrexate.
Another misconception is that biologics are always better than conventional DMARDs. In reality, methotrexate remains the gold standard for initial treatment. The ACR guidelines recommend starting with methotrexate unless contraindicated. Biologics are reserved for patients who fail to respond after 3-6 months of optimized conventional therapy.
Some patients discontinue medication during symptom improvement. This leads to flares in 60% of cases within six months. A 2020 cohort study showed that discontinuation was linked to higher joint damage scores at two-year follow-up. Consistent adherence is critical-even when feeling well.
A 45-year-old woman presents with morning stiffness lasting over an hour, swollen wrists and knees, and elevated RF and anti-CCP antibodies. She has 12 tender joints and 8 swollen joints on exam. Ultrasound shows synovitis in both wrists.
She begins methotrexate at 7.5 mg weekly, with folic acid 1 mg daily to reduce side effects. After four weeks, her joint count drops to 6 tender and 3 swollen. Her CRP falls from 45 mg/L to 12 mg/L. After 12 weeks, she still has mild joint swelling. Her rheumatologist adds adalimumab at 40 mg every two weeks.
After 24 weeks, she achieves low disease activity (DAS28 score < 3.2). She maintains this state for two years with stable medication. No new joint erosions appear on follow-up X-rays. This reflects the success of early, combination therapy guided by clinical response.
During a routine visit, she reported fatigue and mild nausea. Blood tests revealed mild anemia and elevated liver enzymes. Methotrexate was reduced to 10 mg weekly, and liver function improved over eight weeks. This illustrates the need for ongoing monitoring-not just for efficacy, but for safety.
RA inflammation differs from acute injury-related inflammation. While NSAIDs work well for sprains or tendonitis, they fail in autoimmune conditions because they don't address the underlying immune dysregulation. The immune system in RA produces cytokines like TNF-alpha and IL-17 continuously. Blocking these requires targeted therapies-not general anti-inflammatories.
One non-obvious fact: Some patients with RA have normal CRP levels despite active disease. This occurs in 15-20% of cases, especially in those with high disease burden. Relying solely on CRP can delay diagnosis. The ACR recommends combining clinical assessment, imaging, and autoantibody testing for accurate evaluation.
When I managed a patient with persistent joint pain and normal CRP, ultrasound revealed synovial thickening and power Doppler signal. Starting methotrexate led to resolution of both symptoms and imaging findings. This reinforced that laboratory values alone don't capture disease activity.
Early treatment with DMARDs prevents irreversible joint damage. Delaying therapy beyond six months increases the likelihood of permanent deformity. The ACR emphasizes treating within three months of symptom onset to maximize functional recovery.
Understanding what medications are used to treat rheumatoid arthritis means recognizing that treatment is not one-size-fits-all. It involves choosing the right drug at the right time based on disease severity, comorbidities, and patient preferences. Combination therapy often yields better results than monotherapy.